OXGENE—founded in 2011 as Oxford Genetics Ltd. and re-branded in 2019—will continue operations under its own name as a wholly-owned subsidiary of WuXi AppTec’s cell and gene therapy business unit . . .
Home Magazine April 2021 Vol. 41 No. 4 OXGENE Eyes Further Growth in Cell and Gene Therapy Services after Acquisition...
- Magazine
- April 2021 Vol. 41 No. 4
- Cell Therapy
- Outsourcing
- Contract Development
- Contract Manufacturing
- Contract Research
- Contract Services
- Drug Discovery
- GEN Edge
- Genome Editing
- Gene Therapy
OXGENE Eyes Further Growth in Cell and Gene Therapy Services after Acquisition by WuXi AppTec
$135M purchase expands global CTDMO into Europe, broadens buyer’s offerings for advanced therapy developers
One of OXGENE’s automated liquid handling systems, among the company’s high throughout discovery and biomanufacturing platforms powered by advanced robotics. WuXi AppTec has acquired the British contract R&D services provider for $135 million, in a deal that gives the Shanghai-based biopharma its first European facility, and broadens its portfolio of technologies for designing and developing scalable cell and gene therapies. [OXGENE]
